US FDA grants final approval for generic Viagra

10 March 2016

Yesterday, the US Food and Drug Administration approved the first generic version of Viagra (sildenafil citrate) for the treatment of erectile dysfunction.

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA) received clearance to market generic sildenafil citrate tablets in 25mg, 50mg, and 100mg strengths and has 180-day exclusivity to the Pfizer (NYSE: PFE) originated blockbuster ED drug.

Teva previously gained tentative FDA approval for its generic Viagra and has been selling its copy drug since June 2013 in Europe, where dozens of other generics are also available.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK